HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics' Gout Discovery Pipeline
/PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of...
United States Robert Stoffel Ryan Feaver Prnewswire Hemoshear Therapeutics Inc Fifth Milestone Achieved Novel Compounds
Source: prnewswire.com